Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / GLAXF - SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

GLAXF - SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

GlaxoSmithKline Plc
  • Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022.
  • Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma.
  • The global multiple myeloma market is expected to reach $19.8 billion by 2027.
  • Most recent partnership for SpringWorks' Nirogacestat was with AbbVie, and it becomes 7th one targeting patients with multiple myeloma.

For further details see:

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Stock Information
Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com
Menu
GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...